Is mycophenolate mofetil a new treatment for pityriasis lichenoides? A case report
Authors
Abstract:
Pityriasis lichenoides is an uncommon, acquired, papulosquamous disorder that exhibits various clinical presentations, including acute, chronic, and febrile ulceronecrotic Mucha- abermann forms. Pityriasis lichenoides chronica (PLC) is the chronic form of this continuum. Its treatment is challenging for patients and clinicians and some cases are multidrug resistant. Today, this disorder has many treatment choices, including topical corticosteroids, topical calcineurin inhibitors, phototherapy (ultraviolet (UV) A and narrow band UVB), methotrexate, dapsone, cyclosporine and recently etanercept. In our experience, mycophenolate mofetil was effective as a new treatment for pityriasis lichenoides.
similar resources
Treatment of a refractory case of pyoderma gangrenosum with cyclosporine and mycophenolate mofetil
Pyoderma gangrenosum is a rare non infectious neutrophilic dermatosis commonly associated with underlying systemic disease. Many treatment regimens have been reported. Herein, we report a case of refractory pyoderma gangrenosum with good response to combination of cyclosporine and mycophenolate mofetil.
full textSuccessful desensitization to mycophenolate mofetil: a case report.
Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disorder with a wide range of clinical features. Diagnosis is based on clinical assessment supported by investigations, including autoantibody determinations [1]. In a significant number of patients, SLE can cause nephritis, which can result in renal failure, with significant morbidity and mortality [2]. The immunosuppressive...
full textMycophenolate mofetil--a new atheropreventive drug?
Atherosclerosis is a form of chronic inflammation in which endothelial cell dysfunction, fibroproliferative process, oxidative stress and inflammatory cell activation are linked to plaque development and destabilization. T-lymphocytes also play a key role in pathogenesis of atherosclerosis. As a consequence, the suggested concept that modulation of an immunological response could be an appropri...
full textTreatment of Complicated Henoch-Schönlein Purpura with Mycophenolate Mofetil: A Retrospective Case Series Report
Background. Henoch-Schönlein purpura (HSP) is the most common childhood vasculitis with an incidence of approximately 10 per 100 000 children. There is some evidence to support steroid therapy in the treatment of severe abdominal pain, severe nephritis, and central nervous system involvement. However, the routine use of corticosteroids is controversial. Frequent relapses, lack of response to st...
full textMycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum.
An 18-year-old woman with Crohn disease was referred by her gastrointestinal surgeon for treatment of possible peristomal pyoderma gangrenosum (PPG). She had undergone a total proctocolectomy with ileoanal anastomosis when she was 10 years old. Her inflammatory bowel disease (IBD) had been quiescent for a few years; however, she had an acute onset of anal fistulas and pouchitis, which led to a ...
full textMycophenolate mofetil treatment for IgA nephropathy: a meta-analysis.
BACKGROUND Worldwide, IgA nephropathy (IgAN) is the most common type of glomerulonephritis. Mycophenolate mofetil (MMF) is relatively selective for lymphocytes and inhibits antibody production by B cells more than other immunosuppressants. Several randomized controlled trials (RCTs) have analyzed the role of MMF in patients with IgAN. We conducted this meta-analysis of all available RCTs to asc...
full textMy Resources
Journal title
volume 18 issue 4
pages 179- 181
publication date 2015-10-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023